Abstract
The present work is aimed to develop new oral drug delivery systems of 5-fluorouracil for the treatment of colorectal cancer by using hydrophilic swellable polymer hydroxy propyl methyl cellulose (HPMC) and pH responsive soluble polymer Eudragit L100 (ED) as coating materials. Core tablets containing 50mg of 5-fluorouracil were prepared by direct compression. The core tablets compression coated with different ratios (9:1, 8:2, 7:3, 6:4 and 5:5) of HPMC and ED with a coat weight of 300 and 400mg. All the formulations were evaluated for the hardness, friability, drug content uniformity and in vitro drug release studies in media of different pH 1.2, 7.4 and 6.8. The formulations released 0 to 7% of the drug in physiological environment of stomach and small intestine depending upon proportion of HPMC and ED used in the coat. Among the different ratios used for coating with HPMC:ED combination, ratio 9:1 gave the best release profile with the coat weight of 300mg (1.34% in the initial 5h and 87% in 24 h). Further increase in the coat weight to 400mg with different ratios of 9:1, 8:2, 7:3, 6:4 and 5:5 led to drug release of 0%, 0%, 0%, 3.47% and 6.25%, respectively in the initial 5 h and 73.52%, 87.03%, 92.18%, 96.33% and 97.61%, respectively, in 24 h. Thus, based on the results of in vitro drug release studies, the ratio 7:3 with a coat weight of 400mg was found to be suitable for targeting 5-fluorouracil to the colon without being released in physiological environment of stomach and small intestine. The formulation showed no change in physical appearance, drug content or in vitro release pattern after storage at 40° C / 75% RH for 3 months. The release of 5-fluorouracil from developed formulation was directly proportional to amount of ED used in the coat. The DSC and FTIR studies indicated no possibility of interaction between 5-fluorouracil and excipients.
Keywords: 5-fluorouracil, compression-coat, Colon specific drug delivery, HPMC, eudragit L 100, colon targeting, colon, direct compression coating, time-dependent drug delivery, pH responsive polymer, oral drug delivery and compression-coated tablets
Current Drug Delivery
Title: Development of Novel Combined Time and pH-Dependent based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon
Volume: 8 Issue: 5
Author(s): M. Sidramappa Chickpetty, Raga Baswaraj and G. Sunil Kumar
Affiliation:
Keywords: 5-fluorouracil, compression-coat, Colon specific drug delivery, HPMC, eudragit L 100, colon targeting, colon, direct compression coating, time-dependent drug delivery, pH responsive polymer, oral drug delivery and compression-coated tablets
Abstract: The present work is aimed to develop new oral drug delivery systems of 5-fluorouracil for the treatment of colorectal cancer by using hydrophilic swellable polymer hydroxy propyl methyl cellulose (HPMC) and pH responsive soluble polymer Eudragit L100 (ED) as coating materials. Core tablets containing 50mg of 5-fluorouracil were prepared by direct compression. The core tablets compression coated with different ratios (9:1, 8:2, 7:3, 6:4 and 5:5) of HPMC and ED with a coat weight of 300 and 400mg. All the formulations were evaluated for the hardness, friability, drug content uniformity and in vitro drug release studies in media of different pH 1.2, 7.4 and 6.8. The formulations released 0 to 7% of the drug in physiological environment of stomach and small intestine depending upon proportion of HPMC and ED used in the coat. Among the different ratios used for coating with HPMC:ED combination, ratio 9:1 gave the best release profile with the coat weight of 300mg (1.34% in the initial 5h and 87% in 24 h). Further increase in the coat weight to 400mg with different ratios of 9:1, 8:2, 7:3, 6:4 and 5:5 led to drug release of 0%, 0%, 0%, 3.47% and 6.25%, respectively in the initial 5 h and 73.52%, 87.03%, 92.18%, 96.33% and 97.61%, respectively, in 24 h. Thus, based on the results of in vitro drug release studies, the ratio 7:3 with a coat weight of 400mg was found to be suitable for targeting 5-fluorouracil to the colon without being released in physiological environment of stomach and small intestine. The formulation showed no change in physical appearance, drug content or in vitro release pattern after storage at 40° C / 75% RH for 3 months. The release of 5-fluorouracil from developed formulation was directly proportional to amount of ED used in the coat. The DSC and FTIR studies indicated no possibility of interaction between 5-fluorouracil and excipients.
Export Options
About this article
Cite this article as:
Sidramappa Chickpetty M., Baswaraj Raga and Sunil Kumar G., Development of Novel Combined Time and pH-Dependent based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon, Current Drug Delivery 2011; 8 (5) . https://dx.doi.org/10.2174/156720111796642246
DOI https://dx.doi.org/10.2174/156720111796642246 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Current Medicinal Chemistry Editorial [Hot Topic: Targeted Cancer Therapies: Current Status and Future Directions (Guest Editors: Ioannis Starakis)]
Current Medicinal Chemistry Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer
Current Pharmaceutical Design Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Lgr5 Contributes to Intestinal Metaplasia During Gastric Carcinogenesis: A Meta analysis
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Metabolism of Dietary Flavonoids in Liver Microsomes
Current Drug Metabolism